Samar H. Ibrahim, M.B., Ch.B., studies protective mechanisms against the development of nonalcoholic steatohepatitis (NASH).
NASH is considered the hepatic manifestation of the metabolic syndrome. It is closely linked to obesity and insulin resistance, and well-recognized as the most common cause of liver disease in developed countries.
Dr. Ibrahim's main focus is exploring in vitro and in vivo mechanisms that prevent lipoapoptosis (the key pathogenic mechanism of NASH), inflammation, and fibrosis of the liver through genetic and pharmacological manipulations.
Significance to patient care
The ultimate goal is to gain a mechanistic insight into the cellular and molecular mechanisms involved in NASH pathogenesis and identify therapeutic targets that treat and prevent human NASH progression to irreversible end-stage liver disease.